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Summary Evidence in the literature suggests that hyperthermia (HT) or inhibitors of calmodulin can increase
the sensitivity of rodent cells to bleomycin (BLM) by interfering with DNA repair functions. In an attempt to
explore methods of improving the efficacy of thermochemotherapy we have investigated the individual and
combined effects of HT (440C) and the calmodulin inhibitor trifluoperazine (TFP, 30ygm1-1) on early
plateau phase monolayer cultures of mouse EMT6 tumour cells for simultaneous exposures to BLM. Early
plateau phase cultures are relatively resistant both to HT and to BLM. The selected HT and TFP regimens
(either alone or in combination) were non-toxic. Comparing the sensitizing effect (given by the ratio:
DoBLM/Do BLM+modifier) of the various regimens on BLM-treated cells, we found that: TFP alone had a
marginal effect (ratio 1.3), HT alone showed significant potentiation (ratio 19) and the combination of HT
and TFP strongly sensitized (ratio > 110) cells to BLM cytotoxicity. We propose that the use of calmodulin
inhibitors in thermochemotherapy is worthy offurther evaluation.
The bleomycins are a group of glycopeptide anti-
biotics which have activity against a variety of
human and animal tumours. The clinical
preparation (a copper-free mixture of bleomycins
with a predominant bleomycin A2 component) is
used most often in combination with other chemo-
therapeutic agents (for review see Carter et al.,
1978). It is well established that bleomycin (BLM)
can induce cleavage of DNA (for review see Hecht,
1979) and it is generally considered that this
property is responsible for the cytotoxicity of the
antibiotic.
An interesting although variable feature of in
vitro survival curves for bleomycin-treated cells is a
biphasic response in which cell killing appears to be
less efficient at high drug concentrations (Terasima,
1979; for review see Twentyman, 1984). This
resistance of cells does not appear to relate
consistently to cells of a given cell-cycle age or sub-
populations with inherent resistance (Fox, 1984),
but is of obvious importance in determining the
effectiveness of bleomycin in the clinical situation.
It is well recognised that hyperthermia can enhance
the cytotoxic effect of bleomycin (Braun & Hahn,
1975; Hahn et al., 1975), and the principal benefit
of such a combination treatment is the elimination
of the drug-resistant portion of the survival
response.
Correspondence: P.J. Smith.
Received 15 July 1985; and in revised form 14 October
1985.
It has been suggested that the mechanism for
hyperthermic potentiation of BLM toxicity involves
the inhibition of DNA repair functions (Meyn et
al., 1979). Recently it has been shown (Chafouleas
et al., 1984) that inhibitors of calmodulin (a
calcium binding protein involved in various
processes including the regulation of cell
proliferation; Means et al., 1982) activity can
inhibit the recovery of rodent cells from potentially
lethal damage induced by bleomycin, suggesting a
role for calmodulin in DNA repair pathways.
We have studied the interaction of HT and a
calmodulin inhibitor (trifluoperazine, TFP; Weiss et
al., 1982) in modifying the cytotoxic action of
BLM. Our objective was to establish a non-toxic
protocol for increasing the efficacy of the
hyperthermia potentiation of BLM activity. We
have selected an in vitro system which permits the
generation of relatively BLM-resistant cell cultures
to mimic the resistant phenotype displayed by the
majority of tumour cell types in vivo (for review see
Twentyman, 1984).
Materials and methods
Cell culture
The cells used in all experiments were
EMT6/Ca/VJAC, details of which have previously
been published (Twentyman & Bleehen, 1975). Cells
were maintained in monolayer culture by the
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seeding of 1.5 x 10 cells in 5ml of Eagles MEM
supplemented with 10% foetal bovine serum, 1 mM
glutamine and antibiotics, and incubated in 8%
CO2 in air at 37°C. Culture medium was replaced
with fresh medium 2h prior to experimental
manipulations.
Drugs
Bleomycin sulphate (Lot No. U9U1OAS8; Nippon
Kayaku Co., Tokyo) was donated by Lundbeck
Ltd (Luton, UK) with a potency originally assayed
as 1.7mg(potency)mg-1 solid. Manufacturer's
analyses indicated that 68.7% of the preparation
was bleomycin A2 and copper content was
<0.008%. All experiments involved freshly
prepared bleomycin stock solutions in PBS A and
exact concentrations of drug were determined
spectrophotometrically (absorbance of a 1%
solution at 294nm, using a 1 cm path length taken
as 121.5). All bleomycin (BLM) concentrations
refer to weight of solid drug in complete growth
medium. Trifluoperazine (TFP) was obtained from
Sigma and filter-sterilised stock solutions
(2000 igml -1 distilled water) were prepared
immediately prior to use.
Cell survival
Cells were detached from treated flasks by a brief
exposure to trypsin/versene, the cells were counted
and diluted in pre-warmed growth medium
dispensed at 2.5 x 102-2.5 x 103 cells per 9cm
plastic dish and incubated at 37°C for 10 days for
the estimation of viability by clonogenic potential.
Cell survival curves were generated by the analyses
of collected data points using a linear trans-
formation of the multi-target equation as described
by Watson (1978).
Hyperthermia treatment
Flasks containing monolayer cultures were sealed
using paraffin-wax film and submerged in a rapidly
stirred water bath maintained at 44°C for the
period specified. Temperature equilibration occured
within 1 min.
Results
Effect of culture age on bleomycin and hyperthermia
toxicity
A previous study (Twentyman & Bleehen, 1975)
had indicated that the sensitivity of EMT6 cells to
bleomycin varied during the life of the monolayer
cultures. We report here, preliminary studies to
establish standard culture conditions for the
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Figure 1 In vitro growth of mouse EMT6 cells
following an initial inoculum of 1.5 x 105 cells. (@) no
medium change; (0) medium replaced at 1 day
intervals starting on day 2.
generation of cells used in the main investigation on
the interaction of HT, TFP and BLM.
Figure 1 shows the change in the number of cells
per flask with time after inoculation of 1.5 x 105
cells, either with or without daily medium changes
starting on day 1. Similar initial experimental
growth rates were achieved under both conditions,
although the re-feeding of cultures permitted a
higher cell number to be achieved and prevented
early cell detachment. Unfed cultures reached
plateau phase between day 2 and day 4. Flow
cytometric analyses (experimental data not shown)
of cell cycle distributions indicated that unfed cells
on day 4 comprised 74.9% G1 phase, 15.2% S
phase and 9.9% G2 +M phase compared to 25.8%
G1 phase, 47.3% S phase and 26.9% G2+M phase
for exponentially growing cultures. The bleomycin
toxicity data shown in Figure 2 demonstrate the
expected resistance of early plateau phase cultures
(Twentyman & Bleehen, 1975) and the
corresponding hyperthermia toxicity data presented
in Figure 3 indicate that early plateau phase
cultures are also more resistant to hyperthermia
(44°C).
A standard cell culture protocol of unfed cultures
maintained for 4 days was selected on the basis of
the above experiments. The rationale being as
follows: (i) the procedure results in the earliest
generation of the plateau phase state without
culture overcrowding, (ii) early plateau phase
cultures are more resistant to heat and bleomycin
and therefore offer a suitable case for the use of an
agent such as TFP in the interaction studies, and
(iii) it is important that in the biophysical studies
(Smith et al., 1985) a relatively homogenous
population is analysed (75% G1, for day 4
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Figure 4 Treatment protocols for mouse EMT6 cells
exposed to hyperthermia (HT), TFP, BLM or a
combination of agents.
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Figure 2 Effect of culture age on the bleomycin (2h
drug exposure) survival responses of mouse EMT6
cells. (0) day 4 (early plateau phase) cultures; (0) day
2, (exponential phase) cultures. Datum points
represent values from individual experiments.
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Figure 3 Effect of culture age on the hyperthermia
responses of mouse EMT6 cells. (0) day 4 (early
plateau phase) cultures; (Q) day 2 (exponential phase)
cultures. Datum points represent values (+s.e.) from
individual experiments.
cell populations are representative of events within
individual cells.
Potentiation ofBLM toxicity by HT and TFP
A series of preliminary studies established that early
plateau phase cultures of EMT6 cells were
sensitized to BLM to a greater extent when both
drug and heat treatments were simultaneous,
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Figure 5 Effects of hyperthermia and TFP on the
cytotoxicity of BLM towards early plateau phase
EMT6 cells. Data derived from two independent
experiments (s.e. < 15%). Refer to Figure 4 for
treatment protocols. (0) control; (0) HT; (A) TFP;
(-) combined HT and TFP treatment.
inkeeping with the findings of Lin et al. (1983). In
attempting to design a treatment protocol in which
the effects of the individual components were
maximized and which would also permit inter-
pretation at the level of biophysical studies we
have employed the schedule outlined in Figure 4.
The schedule allows for a 15min pretreatment
period for TFP exposures and the simultaneous
treatment of cells with BLM, TFP and HT. This
approach was adopted in the survival studies shown
in Figure 5. The HT and TFP treatments employed
were not toxic, in the absence of BLM, to early
plateau phase cultures (Table I). The survival
curves can be compared on the basis of the Do
values (Table I). TFP alone produced a marginal
potentiation of BLM toxicity the effect mainly
being a reduction in extrapolation number (n
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Table I BLM survival curve parameters for early plateau phase EMT6 cells
Viabilityb BLM cytotoxicityc Do control
Treatmenta (%P.E.) Do (95% confJ limits) Do treated
control 77+1 28.1 (18.5-58.7) set at 1.0
TFP 77+9 21.4 (17.9-26.6) 1.3
HT 77+8 1.5 (1.1-2.7) 18.7
HT+TFP 73+2 0.25 (0.18-0.4) 112.4
aSee Figure 4 for details; bMean absolute
cParameters derived from data in Figure 5.
control=1.38; n TFP=0.43). HT alone strongly
enhanced BLM toxicity and the combination of HT
and TFP produced a high degree of sensitization.
Comparing the various treatments on the basis of
the ratio [Do BLM/Do BLM+modifier] indicates a
synergistic interaction between HT and TFP in
enhancing BLM cytotoxicity some 112-fold.
Discussion
In this report we provide evidence that non-toxic
doses of a calmodulin inhibitor (TFP) can interact
with sub-toxic levels of HT greatly to enhance the
sensitivity of mouse EMT6 tumour cells to BLM.
The effects were observed in early plateau phase
cultures of cells which were shown to exhibit a
resistant phenotype for both BLM and HT
cytotoxicity. Our results suggest a role for
calmodulin in controlling BLM sensitivity and
perhaps the drug potentiation effects of HT.
Twentyman (1984) has noted that there is no
general consensus of opinion regarding the cell-
cycle phase specificity of BLM despite considerable
interest in the possibility that BLM is selectively
toxic to non-cycling cells. EMT6 cells are most
resistant to BLM when in early plateau phase.
Maintenance of cells in plateau phase for prolonged
periods results in an increase in sensitivity
eventually surpassing that of exponential phase cells
(Twentyman & Bleehen, 1975; Twentyman, 1976).
In our HT/TFP interaction studies we have selected
the most resistant situation (i.e. early plateau phase)
in which the majority of the cells are in a Gi
arrested state. Although phenothiazines, such as
TFP, have pleiotropic effects on mammalian cells
(Osborn & Weber, 1980; Means et al., 1982) it is
reasonable to assume that the BLM-sensitization
effects relate to calmodulin dependent processes
given the similar effectiveness of the structurally
dissimilar anticalmodulin drug, W13 (Chafouleas et
al., 1984). It is possible that intracellular levels of
calmodulin may dictate the cell-cycle phase
responsiveness to BLM, since specific synthesis of
this protein occurs at the G1/S boundary (Means et
al., 1982). Thus, in early plateau phase cultures, a
plating efficiency (±s.e.) for 4 experiments;
high level of calmodulin could provide an optimal
environment for DNA repair (Chafouleas et al.,
1984) and hence contribute to cellular resistance.
Calmodulin has a half-life of - 24h in
exponentially growing mouse 3T3 cells (Chafouleas
et al., 1981) suggesting that cells held for a
prolonged period in a G1 arrested state may
become depleted of calmodulin with a concomitant
reduction in cellular resistance to BLM. In any
case, the critical dependence of anti-calmodulin
drugs on cell-cycle age for their BLM-sensitizing
effects is clearly shown by the high degree of
sensitization observed in exponentially growing
rodent cells (Chafouleas et al., 1984) compared to
the marginal level of sensitization noted in our
current experiments.
It is appropriate to consider the mechanisms by
which the BLM-sensitization occur. TFP is known
to have significant effects on the organization of
submembranous microfilaments in rodent cells
resulting in changes in cell surface morphology
(Osborn & Weber, 1980). Interestingly, the BLM-
sensitizing agents ethanol (Mizuno, 1981) and
hyperthermia (vide supra) apparently inactivate cells
by a similar process which appears to involve
changes in membrane fluidity (Li et al., 1980).
Furthermore, our finding of an unusual cytotoxic
interaction between HT, TFP and BLM is similar
to the reported synergistic interaction between
ethanol and hyperthermia in inducing cell
sensitization to BLM (Ishida & Mizuno, 1981).
Such correlations suggest a similar mechanism for
sensitization, perhaps involving membrane struc-
tures (e.g. nuclear membranes) or membrane depen-
dent structures. The roles of DNA repair and events
at the nuclear matrix in cells sensitized to the action
of BLM are explored in the accompanying paper
(Smith et al.. 1986).
We conclude that the combination of anti-
calmodulin drugs in antitumour treatment regimens
involving chemotherapy and hyperthermia is
worthy of further evaluation in vitro and in vivo.
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